New drug combo aims to tame cirrhosis complications
NCT ID NCT06269484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a combination of two drugs, zibotentan and dapagliflozin, is safe for people with cirrhosis, a serious liver condition. 73 adults with cirrhosis took part, receiving either the drug combo, zibotentan alone, or a placebo. The main goal was to check for side effects like fluid retention, which can worsen cirrhosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zibotentan and dapagliflozin
What this could lead to
If successful, this could point toward a safer treatment option for cirrhosis, potentially reducing fluid buildup and complications.
What could go wrong
This is an early Phase 2 safety study with only 73 participants, so results may not apply to all patients. The drugs may cause side effects like fluid retention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Englewood, Colorado, 80113, United States
-
Research Site
Charleston, South Carolina, 29425, United States
-
Research Site
San Antonio, Texas, 78215, United States
-
Research Site
Adelaide, 5000, Australia
-
Research Site
Kogarah, 2217, Australia
-
Research Site
Mitcham, 3132, Australia
-
Research Site
Mechelen, 2800, Belgium
-
Research Site
Liberec, 460 63, Czechia
-
Research Site
Mladá Boleslav, 293 01, Czechia
-
Research Site
Prague, 140 21, Czechia
-
Research Site
Leipzig, 04103, Germany
-
Research Site
Tübingen, 72076, Germany
-
Research Site
Milan, 20122, Italy
-
Research Site
Padova, 35128, Italy
-
Research Site
Roma, 00168, Italy
-
Research Site
Gifu, 500-8513, Japan
-
Research Site
Kawasaki-shi, 215-0026, Japan
-
Research Site
Kitakyusyu-shi, 806-8501, Japan
-
Research Site
Nagaoka-shi, 940-2085, Japan
-
Research Site
Niigata, 951-8520, Japan
-
Research Site
Sapporo, 006-8555, Japan
-
Research Site
Yokohama, 236-0004, Japan
-
Research Site
Bydgoszcz, 85-794, Poland
-
Research Site
Katowice, 40-081, Poland
-
Research Site
Mysłowice, 41-400, Poland
-
Research Site
Poznan, 61-848, Poland
-
Research Site
Bratislava, 83104, Slovakia
-
Research Site
Nitra, 950 01, Slovakia
-
Research Site
Trnava, 91702, Slovakia
-
Research Site
Aberdeen, AB25 2ZN, United Kingdom
-
Research Site
Hull, HU3 2KZ, United Kingdom
-
Research Site
Ipswich, IP4 5PD, United Kingdom
-
Research Site
London, SE5 9RS, United Kingdom
-
Research Site
Nottingham, NG7 2UH, United Kingdom